Biopharma continues to provide attractive opportunities for investors
Biopharma is leveraging a variety of funding mechanisms to support obesity R&D. Venture capital, IPOs, and share issues are fueling early-stage innovation, with Series A rounds playing a critical role in helping startups progress into clinical development.
Investors that have acquired and kept shares in small-mid size pharma may well reap significant rewards with companies such as Zealand, Viking and Structure remaining strong players in the space with very promising candidates.
A key metric of interest is the volume of venture dollars flowing into companies in a given therapeutic area. The chart below shows that investment is up tenfold between 2025 and 2019 and that investments over the last years are up quite substantially from prior years.
